Relay Therapeutics Q3 net loss $84.2M ($0.76/sh); RLY-4008 88% ORR in FGFR2-fusion CCA

Relay Therapeutics, Inc.

2022-Q3 EPS reported -$2.04 revenue$1,128,000

Net loss $84.2M vs $60.8M YoY; R&D expenses rose to $66.9M from $45.0M.
Cash and investments $1.1B as of Sep 30, 2022; sufficient to fund operations into 2025.
RLY-4008 interim data: 88% ORR at pivotal dose in FGFRi-naive FGFR2-fusion cholangiocarcinoma (n=17).
Raised $300M gross proceeds in follow-on public offering during Q3.
RLY-2608 (PI3Kα inhibitor) continues enrolling in single-agent and combination cohorts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Relay Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76, EPS $0.76.

Period: the quarter ended September 30, 2022
Net income: Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76
EPS: $0.76
Result: reported results

Exact text from the filing

Relay Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.